GSK1349572 Relative Bioavailability Study

Summary

GSK1349572 Relative Bioavailability Study is a clinical trial^[1].

Key Facts

• GSK1349572 Relative Bioavailability Study is in the country of United States^[2].
• GSK1349572 Relative Bioavailability Study's instance of is recorded as clinical trial^[3].
• GSK1349572 Relative Bioavailability Study's start time is recorded as +2010-04-30T00:00:00Z^[4].
• GSK1349572 Relative Bioavailability Study's end time is recorded as +2010-06-30T00:00:00Z^[5].
• GSK1349572 Relative Bioavailability Study's main subject is recorded as HIV^[6].
• GSK1349572 Relative Bioavailability Study's number of participants is recorded as {'unit': '1', 'amount': '+24'}^[7].
• GSK1349572 Relative Bioavailability Study's title is recorded as Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674)^[8].
• GSK1349572 Relative Bioavailability Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[9].
• GSK1349572 Relative Bioavailability Study's ClinicalTrials.gov ID is recorded as NCT01098513^[10].
• GSK1349572 Relative Bioavailability Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[11].
• GSK1349572 Relative Bioavailability Study's research intervention is recorded as dolutegravir^[12].
• GSK1349572 Relative Bioavailability Study's clinical trial phase is recorded as phase I clinical trial^[13].
• GSK1349572 Relative Bioavailability Study's research site is recorded as GSK^[14].
• GSK1349572 Relative Bioavailability Study's research subject recruitment status is recorded as completed^[15].
• GSK1349572 Relative Bioavailability Study's research subject recruitment status is recorded as completed^[16].
• GSK1349572 Relative Bioavailability Study's study type is recorded as interventional study^[17].